Resistant hypertension represents a significant burden for healthcare systems worldwide due to its association with extremely high cardiovascular risk and remains a therapeutic challenge driven by complex and inadequately addressed by conventional therapy pathophysiological pathways. Several drugs in various stages of investigation could potentially have a significant impact on the ultimate treatment of resistant hypertension. In addition to pharmacological therapy, studies show promising evidence regarding renal artery denervation in managing resistant hypertension. Better usage of currently approved therapies and the integration of emerging therapies are welcomed additions to the anti-hypertensive therapeutic arsenal.
No takes yet. Share an insight, caveat, or question.
Caraus et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: